Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zheng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0490-466X; OpenAlex author ID A5100401079, A5121912553. Sources: ClinicalTrials.gov.

Their work

Papers
56 (first author 2, last author 20)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
100
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 3 papers · 2014: 3 papers · 2015: 4 papers · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 5 papers · 2020: 5 papers · 2021: 1 paper · 2022: 10 papers · 2023: 2 papers · 2024: 4 papers, 2 trials · 2025: 6 papers · 2026: 3 papers

Papers 50 of 56

  1. Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c-Met Expression. Co-author DOI 10.1002/ptr.70176↗
  2. MUC15 loss promotes perineural invasion in pancreatic cancer by activating the IGF1R/STAT3/NGF pathway. Last author DOI 10.1016/j.canlet.2026.218362↗
  3. Post-pancreatectomy chemotherapy improves the survival of patients with late-stage but not early-stage pancreatic cancer. Co-author DOI 10.3389/fonc.2026.1744027↗
  4. Endoscopic ultrasound elastography in solid pancreatic lesions: individual and combined performance of strain ratio, fat-lesion strain ratio, and mean strain h… Co-author DOI 10.1007/s10238-025-01969-5↗
  5. Characterization and treatment of brain metastases from pancreatic cancer: a systematic review. Co-author DOI 10.1007/s12672-025-02623-y↗
  6. TYROBP overexpression alters macrophage phenotype and enhances pancreatic cancer stemness through STAT3 and PKM2 signaling. Last author DOI 10.1016/j.cellsig.2025.111949↗
  7. Targeting IRF7 to overcome gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.114207↗
  8. CXCL Gene Clusters Regulated by Enhancer-Mediated DNA Looping Alteration in Pancreatic Cancer Cells. Last author DOI 10.1111/jcmm.70538↗
  9. Tobacco carcinogen NNK promotes pancreatic cancer proliferation via LINC00857/β-catenin. Last author DOI 10.18332/tid/203455↗
  10. Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing S… Last author DOI 10.1016/j.canlet.2023.216602↗
  11. Pharmacological inhibition of SREBP1 suppresses pancreatic cancer growth via inducing GPX4-mediated ferroptosis. Co-author DOI 10.1016/j.cellsig.2024.111381↗
  12. TYROBP promotes the spread of pancreatic cancer by causing M2 TAM polarization. Last author DOI 10.1111/jgh.16783↗
  13. Resveratrol inhibits pancreatic cancer proliferation and metastasis by depleting senescent tumor-associated fibroblasts. Co-author DOI 10.4251/wjgo.v16.i9.3980↗
  14. Correction to: Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Co-author DOI 10.1007/s00210-023-02499-1↗
  15. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. Last author DOI 10.1016/j.canlet.2022.215976↗
  16. NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy. Last author DOI 10.1002/1878-0261.13230↗
  17. Resveratrol inhibits the expression of RYR2 and is a potential treatment for pancreatic cancer. Co-author DOI 10.1007/s00210-022-02203-9↗
  18. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Co-author DOI 10.1016/j.biopha.2022.112713↗
  19. Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing … Last author DOI 10.1016/j.canlet.2022.215913↗
  20. HGF/c-Met pathway facilitates the perineural invasion of pancreatic cancer by activating the mTOR/NGF axis. Last author DOI 10.1038/s41419-022-04799-5↗
  21. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Last author DOI 10.1038/s41419-022-05082-3↗
  22. Correction: Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Last author DOI 10.1038/s41419-022-05236-3↗
  23. Autophagic Schwann cells promote perineural invasion mediated by the NGF/ATG7 paracrine pathway in pancreatic cancer. Co-author DOI 10.1186/s13046-021-02198-w↗
  24. Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma. Co-author DOI 10.3389/fgene.2022.940794↗
  25. Incidence and risk factors of suicide among patients with pancreatic cancer: A population-based analysis from 2000 to 2018. Co-author DOI 10.3389/fonc.2022.972908↗
  26. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Last author DOI 10.1186/s13046-020-01823-4↗
  27. 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling. Last author DOI 10.1016/j.canlet.2019.11.041↗
  28. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2019-318860↗
  29. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Co-author DOI 10.1155/2020/1868764↗
  30. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  31. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor‑stromal crosstalk under hypoxic conditions via the IL‑6/ERK/NF‑κB axis. Last author DOI 10.3892/or.2020.7600↗
  32. RNA-Binding Motif Protein 6 is a Candidate Serum Biomarker for Pancreatic Cancer. Co-author DOI 10.1002/prca.201900048↗
  33. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway. Co-author DOI 10.1177/0963689719851772↗
  34. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  35. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  36. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  37. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. Co-author DOI 10.1159/000494547↗
  38. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  39. The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway. Last author DOI 10.3892/ijo.2018.4363↗
  40. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  41. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Last author DOI 10.1186/s13046-017-0655-5↗
  42. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
  43. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.3390/nu8100546↗
  44. Resveratrol in the treatment of pancreatic cancer. Co-author DOI 10.1111/nyas.12837↗
  45. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  46. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. First author DOI 10.18632/oncotarget.3069↗
  47. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
  48. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. Last author DOI 10.1016/j.febslet.2014.01.007↗
  49. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Co-author DOI 10.1155/2014/546353↗
  50. The Activation of β1-integrin by Type I Collagen Coupling with the Hedgehog Pathway Promotes the Epithelial-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.2174/1568009614666140402105101↗

Trials 2

  1. The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer Principal investigator NCT06368063↗
  2. Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer Principal investigator NCT06387368↗

Closest collaborators

The 25 strongest of 100 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 41 shared papers, 2011–2025 · strength 4.02
  2. Weikun Qian · 21 shared papers, 2019–2026 · strength 3.40
  3. Zheng Wu · 21 shared papers, 2013–2024 · strength 2.17
  4. Cancan Zhou · 12 shared papers, 2016–2025 · strength 1.50
  5. Wanxing Duan · 21 shared papers, 2012–2022 · strength 1.32
  6. Jiguang Ma · 19 shared papers, 2014–2022 · strength 1.31
  7. Qinhong Xu · 17 shared papers, 2012–2025 · strength 1.15
  8. Xuqi Li · 20 shared papers, 2012–2020 · strength 1.12
  9. Tao Qin · 7 shared papers, 2019–2026 · strength 1.10
  10. Jianjun Lei · 17 shared papers, 2012–2021 · strength 1.08
  11. Ying Xiao · 7 shared papers, 2019–2023 · strength 0.94
  12. Yangyang Yue · 5 shared papers, 2020–2026 · strength 0.87
  13. Weifan Zhang · 6 shared papers, 2022–2023 · strength 0.87
  14. Jiantao Mo · 5 shared papers, 2022–2025 · strength 0.87
  15. Simei Zhang · 5 shared papers, 2022–2026 · strength 0.82
  16. Wunai Zhang · 5 shared papers, 2022–2026 · strength 0.82
  17. Zeen Zhu · 5 shared papers, 2022–2026 · strength 0.82
  18. Zhengdong Jiang · 11 shared papers, 2015–2023 · strength 0.74
  19. Erxi Wu · 13 shared papers, 2011–2022 · strength 0.72
  20. Guotai Wang · 3 shared papers, 2022–2024 · strength 0.62
  21. He Jiang · 3 shared papers, 2022–2024 · strength 0.62
  22. Jie Li · 4 shared papers, 2020–2024 · strength 0.60
  23. Yiqun Song · 2 shared papers, 2026 · strength 0.57
  24. Liang Han · 7 shared papers, 2014–2022 · strength 0.54
  25. Dingwen Zhong · 2 shared papers, 2024–2025 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.